Nuformix PLC Director/PDMR Shareholding (0420M)
September 16 2021 - 7:47AM
UK Regulatory
TIDMNFX
RNS Number : 0420M
Nuformix PLC
16 September 2021
16 September 2021
Nuformix plc
("Nuformix" or the "the Company")
Director/PDMR Shareholding
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, announces that today the Company received notice that
Dr Alastair Riddell, Chairman of the Company, purchased 350,000
ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of
0.0135 pence per share on 16 September 2021.
- Ends -
Enquiries:
Nuformix plc +44 (0) 1223 627 222
Dr Anne Brindley, CEO
Allenby Capital Limited +44 (0) 20 3328 5656
Nick Athanas / George Payne (Corporate
Finance)
Stefano Aquilino / Matt Butlin (Sales
& Corporate Broking)
Walbrook PR +44 (0) 20 7933 8780
Anna Dunphy / Paul McManus nuformix@walbrookpr.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Alastair Riddell
---------------------------- -------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status PDMR - Chairman
---------------------------- -------------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Nuformix plc
---------------------------- -------------------------------------
b) LEI 2138003XG3H3I2J3BJ24
---------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Ordinary Shares of nominal value
financial instrument, 0.1 pence each
type of instrument
Identification code GB00BYW79Y38
---------------------------- -------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
---------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.0135p 350,000
----------
---------------------------- -------------------------------------
d) Aggregated information
- Aggregated volume 350,000
- Price 0.0135p
- Total GBP4,725.00
---------------------------- -------------------------------------
e) Date of the transaction 16 September 2021
---------------------------- -------------------------------------
f) Place of the transaction London Stock Exchange, Main Market
---------------------------- -------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGPUACBUPGGGQ
(END) Dow Jones Newswires
September 16, 2021 07:47 ET (11:47 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024